Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study

• DOI: 10.1111/liv.15320
• Publication Date: 2022-05-24T16:19:21Z
• Authors: Sergio Muñoz‐Mart...; Victor Sapena; Alejandro Forner; Jordi Bruix; Marco Sanduzzi‐Za...; José Ríos; Mohamed Bouattour; Mohamed El‐Kassas; Cassia R. G. Leal; Tudor Mocan; Jean‐Charles Nault; Rogerio C. P. Alves; Helen L. Reeves; Leonardo da Fonseca; Ignacio García‐Ju...; David J. Pinato; María Varela; Saleh A. Alqahtani; Mario R. Alvares‐...; Juan C. Bandi; Lorenza Rimassa; Mar Lozano; Jesús M. González...; Frank Tacke; Margarita Sala; María Anders; Anja Lachenmayer; Federico Piñero; Alex França; Maria Guarino; Alessandra Elvevi; Giuseppe Cabibbo; Markus Peck‐Rados...; Ángela Rojas; Mercedes Vergara; Chiara Braconi; Sonia Pascual; Christie Perelló; Vivianne Mello; Carlos Rodríguez‐...; Juan Acevedo; Rosanna Villani; Clemence Hollande; Valérie Vilgrain; Ahmed Tawheed; Carmem Ferguson T...; Zeno Sparchez; Lorraine Blaise; Daniele E. Viera‐...; Robyn Watson; Flair J. Carrilho; Carlos Moctezuma‐...; Antonio D'Alessio; Massimo Iavarone; Maria Reig
• Keywords: Liver Cancer

Abstract Background & Aims Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in patients with liver cancer is lacking. This study characterizes outcomes and mortality risk this population. Methods Multicentre retrospective, cross‐sectional, international SARS‐CoV‐2 infection registered between February December 2020. Clinical data at diagnosis were registered. Results Two hundred fifty from 38 centres included, 218 hepatocellular carcinoma (HCC) 32 intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 64.5 years, 84.9% 21.9% had cirrhosis HCC iCCA cohorts respectively. Patients advanced stage 39.0% 71.9% patients. After a follow‐up 7.20 (IQR: 1.84–11.24) months, 100 (40%) have died, 48% deaths SARS‐CoV‐2‐related. Forty (18.4%) died within 30‐days. death rate increase significantly different according to BCLC (6.10% [95% CI 2.24–12.74], 11.76% 4.73–22.30], 20.69% 11.35–31.96] 34.52% 17.03–52.78] for 0/A, B, C D, respectively; p = .0017). hazard ratio 1.45 (95% 0.49–4.31; .5032) BCLC‐B versus 3.13 1.29–7.62; .0118) BCLC‐C 0/A competing Cox regression model. Nineteen out (59.4%) 12 related infection. Conclusions largest cohort infected SARS‐CoV‐2. It 30‐day during period.